# Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer

> **NCT02344550** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 137 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Everolimus(afinitor)
- **DRUG:** Letrozole
- **DRUG:** Leuprolide(Lorelin Depot)

## Key facts

- **NCT ID:** NCT02344550
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2018-10
- **Final completion:** 2018-10
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2020-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02344550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02344550, "Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02344550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*